Trials / Unknown
UnknownNCT00872391
Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Safety and Efficacy of Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Malignant Melanoma of the Uvea
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 155 (estimated)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of hypofractionated stereotactic LINAC radiotherapy with 10 fractions at 6 Gy per fraction at the 80% isodose for the planning target volume (PTV) in patients with uveal melanoma. Patients will be followed-up for 10 years after radiotherapy regarding local tumor control, visual acuity, secondary complications and survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionated linear accelerator radiotherapy | 10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2024-03-01
- First posted
- 2009-03-31
- Last updated
- 2009-03-31
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT00872391. Inclusion in this directory is not an endorsement.